Glycemic control: Are new antidiabetic treatments changing the fundamentals of diabetes management?
This lecture was part of a Cardio Diabetes Master Class 'CVM Summit 2017, held on May 5, 2017 in Beijing, China
Educational information
The educational objectives of the program were:
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
- To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a risk based intervention strategy that targets glucose control and cardiovascular risk factors
- To discuss therapies that work through other insulin-related mechanisms, including insulin resistance in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
- To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
- To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients
Disclosures
Prof. Jochen Seufert, MD is professor of Medicine, Endocrinology and Diabetology and Director of the Division of Endocrinology and Diabetology - Freiburg, Germany
Funding
The master class is supported by an unrestricted educational grant provided by Takeda Pharmaceuticals
View slides
The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: